drug discovery 15 - elrig · bedside to bench target identification and target engagement:...
TRANSCRIPT
DRUG DISCOVERY ‘15
2ND - 3RD SEPTEMBER 2015
TELFORD INTERNATIONAL CONFERENCE CENTRE
www.elrig.org
European LaboratoryResearch & Innovation Group
#ELRIGDD15
WELCOME TO DRUG DISCOVERY 2015
We are delighted to welcome you to the 9th annual ELRIG Drug Discovery conference, Drug Discovery 2015 at to our new Telford venue. I hope you will enjoy the excellent conferencing and networking facilities of this venue. We look forward to meeting with you over coffee or beer during the event to get your views on venue, themes, and key issues affecting drug discovery that we can bring into the programme for future years. This Telford & ironbridge region has an amazing heritage of applied innovation - do try to take in the World Heritage Site attractions while you are in the area.
Both myself (Peter & Del) have previously been Drug Discovery conference directors in 2013 and 2014 and we are delighted to welcome Roberto, a great addition to the team for this year; and to acknowledge the great work of Liz Quinn as ELRIG Scientific Program Director in keeping things on track.
The ELRIG Drug Discovery 2015 programme contains a remarkable series of presentations from leading scientists across Europe and beyond, covering advances in basic and translational aspects of drug discovery. The scientific sessions will as usual cover core themes within drug discovery:
Innovation in Assay Development & Screening Chemistry Innovation in Lead Discovery Target Identification & Validation Phenotypic Discovery & Cell Imaging Oncology Drug Targets New Biologic Drugs & Technologies
We are also delighted to introduce two new science sessions this year, firstly a new track on advances in Metabolic and Cardiovascular diseases, which are critical areas for public health around the world. And for the first time we have introduced a track covering the rapidly developing field of Cell & Gene Therapies.
We want to acknowledge the great work of the session chairs in putting together the speaker programmes for these sessions - they have outdone themselves this year with an internationally renowned line-up.We have had some great plenary speakers in recent years, and we are delighted that this year we have secured David Thomas from Montreal, a world-renowned expert in protein trafficking disorders; and Tracy Hussell, head of the unique Manchester Collaborative Centre for Inflammation Research which brings major Pharma and academic experts together to address inflammatory diseases.
Another exciting part of Drug Discovery conference iare the Technology Forums. These were a great success last year, and will again provide a more informal, interactive environment for you to discuss key issues and future directions in workshop-style events coordinated by leaders in the fields. These will address Anti-Infectives; the future of HTS; Enzymology; and Protein-Protein Interactions. Go along and join the discussions!
ELRIG Drug Discovery 2015 will include a high quality scientific poster session, great networking opportunities, and an extensive vendor exhibition - please do quiz the poster presenters, and visit the exhibition to see the range of new products and innovations on display. Don't miss the Innovation Zone, for new and exciting emerging companies and technologies. We are also partnering with the SLAS to bring you a SLAS Author Workshop - a great way to improve your publication skills.
Each year, the ELRIG Drug Discovery conference provides a fantastic communication and learning opportunity for scientists engaged in research fields across drug discovery, bringing together Academia, Biotech, Vendors, & Pharma, into a strong single community of scientists. It is now well established as the leading annual drug discovery event held in the UK. For those of you who have been before, we are glad to see you again; for those of you experiencing DD for the first time - we hope you learn, and have fun, here in Telford.
Regards,
Peter Simpson Del Tresize Roberto Solari
OUR PLENARY KEYNOTE SPEAKERS
SLAS AUTHORS’ WORKSHOP
There is no magic bullet, but there are important tips that every prospective author should know before submitting a scientific manuscript for consideration by a peer-reviewed journal. Julio Martin Plaza, PhD, of GlaxoSmithKline in Tres Cantos, Spain (and member of the Journal of Biomolecular Screening Editorial Board) will share step-by-step advice on how to design and write scientific research papers more clearly and effectively to improve their chances for successful publication. Attendees will learn what editors want, what they don't want, and how reviewers evaluate manuscripts.
Wednesday September 2nd
Room: Jackfield
Protein trafficking diseases are defined by mutant proteins, that are destined for location at the plasma membrane, but are recognized as misfolded by the cellular protein quality control systems, retained in the endoplasmic reticulum (ER), retrotranslocated into the cytoplasm where it is degraded by the proteasome. Some mutants of secretory proteins are in fact functional if they can be induced to traffic to the cell surface. One example is the F508del-CFTR mutant that, when homzygous, causes most of the cases of cystic fibrosis. Screens for correctors of trafficking of F508del-CFTR have identified molecules that allow its correct cellular trafficking. These correctors fall into two general categories. The first are
“pharmacological chaperones” that bind to the mutant F508del-CFTR molecule and promote its folding so that it escapes the quality control systems. The second are “proteostasis modulators” that act on the cellular quality control systems. While the first category of correctors are specific for the mutant F508del-CFTR molecule some of the second category of proteostasis modulators can correct the trafficking of mutant proteins of other protein trafficking diseases.
Alveolar macrophages exist in a unique microenvironment and, despite historical evidence showing that they are in close contact with the respiratory epithelium, have until recently been investigated in isolation. The microenvironment of the airway lumen has a considerable influence on many aspects of alveolar macrophage phenotype, function and turnover. As the lungs adapt to environmental challenges, so too do alveolar macrophages adapt to accommodate the ever-changing needs of the tissue. I will discuss how working in an open innovation, pre-competitive environment with the UK’s largest pharmaceutical companies allows us to explore the unique characteristics of alveolar macrophages, the mechanisms that
drive their adaptation and the direct and indirect influences of epithelial cells on them. I will also highlight how they adapt in the inflamed lung and the processes driving adaptation in a variety of inflammatory conditions. The unique tissue location and function of alveolar macrophages distinguish them from other macrophage populations. However, over-regulation of them in repair leads to bacterial exacerbations. Re-setting the inflammatory tone of the airspaces and particularly airway macrophages presents new therapeutic opportunities.
Professor Tracy HussellDirector of the Manchester Collaborative Centre for Inflammation Research (MCCIR).
The Development of New Therapeutics for respiratory inflammationIronbridge room - 14.00 - Thursday 3rd September
Dr. David ThomasCEO, Traffick Therapeutiques/Thérapeutiques, Inc
Tackling Protein Trafficking DiseasesIronbridge room - 14.00 - Wednesday 2nd September
OUR SCIENTIFIC COMMITTEE
Metabolic & Cardiovascular Drug Discovery Chemistry Innovation In Lead Discovery
Target Identification & Validation Innovation In Assay Development & Screening
Oncology Drug Targets Cell And Gene Therapy
New Biological Drugs & Technologies Phenotypic Discovery & Cell Imaging
Marcus SchindlerAstraZeneca R&D Mölndal
Paul WyattUniversity of Dundee
Michael SchneiderImperial College London
Darren McKerrecherAstraZeneca
Jon MooreHorizon Discovery
Anne PhelanPfizer Neusentis
Hamish RyderCancer Research Technology
Angela GrittiSan Raffaele Telethon Institute
for Gene Therapy (TIGET)
Lutz JermutusMedImmune
Marc BickleMax Planck Institute of
Molecular CellBiology & Genetics
Rachel Grimley AstraZeneca
Steve HillUniversity of Nottingham
Herbie NewellNewcastle University
Aniz GirachNightstaRx
Katy KettleboroughMRC Technology
Steve LudbrookGlaxoSmithKline
PROGRAMME AT A GLANCE
Plenary Keynote: Tackling Protein Trafficking Diseases
Novel Inhibitors of MAP4K4 (HGK), an Acute Therapy to Prevent Cardiac Muscle Cell Death Following Myocardial
Infarction
Unravelling the Molecular Mechanisms of
Proteinuria
Nanotechnology, Imaging and Targeted Drug Therapy
in Cardiac Pathology
The Role of Post-Transcriptional
Regulation in Cardiac Disease
Myocyte Lipotoxicity: A Chemical Biology
Approach
Synthetic Chemically Modified mRNA (modRNA): Towards A New Technology Platform for
Cardiovascular Biology & Medicine
Plenary Keynote: The Development of New Therapeutics for respiratory inflammation
Design of Novel Building Blocks to Enhance Drug
Discovery
Phenotypic Drug Discovery: With A Lot of Help From Our
Friends!
Structure-Kinetic Relationships: Investigating the Molecular
Basis for Optimising Drug-Target Residence Time
All in Good Time, Exploiting Residence Time to Improve
Fragment Based Drug Discovery
Phage Selection of Bicyclic Peptides for Therapeutic
Application
Using Diversity-Oriented Synthesis to Enable
Fragment-Based Lead Discovery
The Role of Systems Biology / Pharmacology in Choosing and
Validating Targets
Mass Spectrometry-Based Discovery Tools for
Epigenetics
The Impact of CRISPR/Cas9 on Target Identification and
Validation
The Application of Synthetic Lethality to Cancer Treatment
New Targets for Virus-Induced Asthma Exacerbations: From
Bedside to Bench
Target Identification and Target Engagement: Applications in
Drug Discovery
The Kinetics of Drug-Receptor Binding: Why It Is Important and How We Can Measure It
Biased Ligand Quantification in Drug Discovery: From Theory to High Throughput Screening to Identify New Biased µ Opioid
Receptor Agonists
Efficacy and Toxicity Assays Using iPS Cells - Utilising Cells
Reset to the Manufacturers Default Setting
Functional Screening of Network Activity in Primary Neuronal
Cultures Using a Novel Phenotypic Assay Platform
Nanobodies in Cell-Based Screening
Phenotypic Screening for Novel Druggable Targets
Using "Protein-Interference"
Optimising Oncology Drug Discovery via Partnerships
Between Academia and Industry
Building On an Atypical (PKC) Relationship –
Innovative Drug Discovery Alliances in Oncology
Targeting Oxygenases for the Regulation of Protein
Biosynthesis
Chemical Probes for the Bromodomain of the BRPF
Family
Fragment-Based Lead Generation of Reversible
Inhibitors for Lysine-Specific Demethylases
“We Must Work Together To Catalyse the Generation of
More Novel and More Affordable Cancer Treatments”
Modelling Cardiovascular Disease with Pluripotent Stem
Cells: a High-Content Approach
Accelerating Human iPSC in vitro Disease Modeling by Introducing
Targeted Gene Mutations in Isogenic Cell Lines Through the CRISPR/Cas9 Nuclease System
Adoptive T cell Therapy for Cancer
Hematopoietic Stem Cell Based Gene Therapy for the Treatment of Lysosomal Storage Disorders
Gene Therapy for Choroideremia, an Inherited
Cause of Blindness
How Stem Cells Signal to Host Immune Cells
Development of Cytotoxic Bicyclic Peptide Drug
Conjugates and Applications in Molecular Targeted Cancer
Therapy
How Information From the Study of Antibody Function Can
be Used in the Discovery of Novel Small Molecule
Therapeutics
XTEN Protein Polymer for Half-Life Extension and Tumor
Drug Delivery
Fine-Tuned T Cell Receptors for Cancer
Immunotherapy
PBD-Based Antibody Drug Conjugates
Towards a New Class of Biotherapeutics Based on
Synthetic Genetic Polymers
Increasing Physiological Relevance, Increasing
Information: High-Content Phenotypic Screening
Compound Screening and Profiling in Cultured Human
Tissues
Mass Spectrometry Imaging in Drug Discovery – Bridging Between Cells and Tissues
Phenotypic Discovery Using Machine Learning and Image
Analysis Methods
KNIME Image Processing - Integrative Open-Source
BioImage Analysis
Phenotypic Screening to Identify Novel Targets for
Discovery
Metabolic & Cardiovascular Drug Discovery
Chemistry Innovation In Lead Discovery
Target Identification& Validation
Innovation In AssayDevelopment & Screening
Oncology Drug Targets Cell And Gene Therapy New Biological Drugs& Technologies
Phenotypic Discovery& Cell Imaging
Day
1: W
edne
sday
2nd
Sep
tem
ber
Day
2: T
hurs
day
3rd
Sept
embe
r
SESSION SUMMMARY
17:00 - 18:00
Introduction and Welcome
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
POSTER SESSION
NETWORKING - DRINKS RECEPTION - DRAGON’S DEN
LUNCH - EXHIBITION - POSTERS
Wednesday September 2nd
Room: Pattingham
TIME SPEAKER TITLESession Chairs
PLENARY KEYNOTE: ROOM - IRONBRIDGE
Tackling Protein Trafficking DiseasesDr David ThomasTraffick Therapeutiques/Thérapeutiques, Inc
METABOLIC & CARDIOVASCULAR DRUG DISCOVERY
Novel Inhibitors of MAP4K4 (HGK), an Acute Therapy to Prevent Cardiac Muscle Cell Death Following Myocardial Infarction
Unravelling the Molecular Mechanisms of Proteinuria
Nanotechnology, Imaging and Targeted Drug Therapy in Cardiac Pathology
The Role of Post-Transcriptional Regulation in Cardiac Disease
Myocyte Lipotoxicity: A Chemical Biology Approach
Cardiovascular and metabolic disorders are the predominant cause of death of disability in the industrialized world and increasingly prevalent in developing nations. Here, we address unmet needs and therapeutic opportunities including: a chemical biology approach to muscle cell lipotoxicity; human stem cell-derived cardiomyocytes as a platform for target validation in suppressing cardiac muscle cell death; genetics, genomics, and epigenomics of metabolism; signalling networks in glomerular kidney disease; nanotechnology and drug delivery; and chemically modified mRNA, a new technology for drug discovery and therapeutics.
Katie ChapmanDomainex
Tobias HuberUniversity of Freiburg
Kim KellyUniversity of Virginia
Norbert HübnerMax-Delbrück-Center for Molecular Medicine (MDC)
Keynote Speaker: Daniel P. KellySanford Burnham Prebys Medical Discovery Institute
CHAIRS: Michael Schneider, Imperial College London. Marcus Schindler, AstraZeneca R&D Mölndal
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 13:50
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 18:00
16:00 - 16:30
Synthetic Chemically modified mRNA (modRNA): Towards A New Technology Platform for Cardiovascular Biology and Medicine
Ken ChienKarolinska Instituet
Afrah Sattikar, MRC TechnologyLaurent Brault, Exquiron
LabLogic, Hamamatsu Phonics UK Limited
13:50 - 14:00 Welcome words from the ELRIG Chairman - Sanj Kumar - IRONBRIDGE
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMARY
17:00 - 18:00
Introduction and Welcome
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
POSTER SESSION
NETWORKING - DRINKS RECEPTION - DRAGON’S DEN
LUNCH - EXHIBITION - POSTERS
Wednesday September 2nd
Room: Beckbury
TIME SPEAKER TITLESession Chairs
PLENARY KEYNOTE: ROOM - IRONBRIDGE
CHEMISTRY INNOVATION IN LEAD DISCOVERY
Design of Novel Building Blocks to Enhance Drug Discovery
Phenotypic Drug Discovery: With A Lot of Help From Our Friends!
Structure-Kinetic Relationships: Investigating the Molecular Basis for Optimising Drug-Target Residence Time
All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery
Phage Selection of Bicyclic Peptides for Therapeutic Application
Using Diversity-Oriented Synthesis to Enable Fragment-Based Lead Discovery
Frederick GoldbergAstraZeneca
Paul WyattUniversity of Dundee
Tackling Protein Trafficking Diseases
Mike WaringAstraZeneca
James MurrayVernalis (R&D) Ltd
Christian HeinisEcole Polytechnique Fédérale de Lausanne (EPFL)
Keynote Speaker: Damian YoungBaylor College of Medicine
Dr David ThomasTraffick Therapeutiques/Thérapeutiques, Inc
The need to create chemical leads for ever more challenging biological targets has led to a need for increased chemical innovation in lead discovery. Recent innovations include the generation of high quality hits outside classical ‘small molecule’ chemical space, the application of emerging synthetic methods and design principles to deliver diverse compound libraries, and greater consideration of conformational and kinetic profiles of potential hits. This session will highlight scientific approaches that increase chemical innovation in lead discovery which, together with novel partnership approaches, may deliver high quality leads for today’s challenging drug targets.
CHAIRS: Darren McKerrecher, AstraZeneca. Paul Wyatt, University of Dundee
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 13:50
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 18:00
16:00 - 16:30
Daniela Natale, IRBM Science Park, SpaFiona Jeganathan, Institute of Cancer Research
Lab Services, EpiSentec
13:50 - 14:00 Welcome words from the ELRIG Chairman - Sanj Kumar - IRONBRIDGE
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMMARY
17:00 - 18:00
Introduction and Welcome
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
POSTER SESSION
NETWORKING - DRINKS RECEPTION - DRAGON’S DEN
LUNCH - EXHIBITION - POSTERS
Wednesday September 2nd
Room: Wenlock
TIME SPEAKER TITLE
Session Chairs
PLENARY KEYNOTE: ROOM - IRONBRIDGE
The Role of Systems Biology / Pharmacology in Choosing and Validating Targets
Mass Spectrometry-Based Discovery Tools for Epigenetics
The Impact of CRISPR/Cas9 on Target Identification and Validation
The Application of Synthetic Lethality to Cancer Treatment
New Targets for Virus-Induced Asthma Exacerbations: From Bedside to Bench
Target Identification and Target Engagement: Applications in Drug Discovery
Neil BensonXenologiq
Pete DiMaggioImperial College London
Tackling Protein Trafficking Diseases
Jon MooreHorizon Discovery
Chris LordInstitute of Cancer Research
Michael EdwardsImperial College London
Keynote Speaker: Friedrich Reinhard Cellzome
Dr David ThomasTraffick Therapeutiques/Thérapeutiques, Inc
TARGET IDENTIFICATION & VALIDATION
CHAIRS: Rachel Grimley, AstraZeneca Jon Moore, Horizon Discovery
The high levels of investment in pharmaceutical R&D over the past decade have not correlated with the number of NMEs gaining approval. Whereas poor PK/PD properties used to be the primary cause of attrition, most New Molecular Entities (NMEs) vs novel targets now fail due to lack of efficacy and/or safety in patient studies. So how can we assure that the right target is selected at the beginning of a drug discovery campaign? And how can we ensure validation enables translation into the clinic? This session covers a range of methodologies and case studies describing key approaches to address these questions.
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 13:50
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 18:00
16:00 - 16:30
Emma Shanks, CRUK Beatson InstituteHelen Boyd, AstraZeneca
NMI (Natural and Medical Sciences Institute), LabCyte, Promega, Molecular Devices
13:50 - 14:00 Welcome words from the ELRIG Chairman - Sanj Kumar - IRONBRIDGE
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMARY
17:00 - 18:00
Introduction and Welcome
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
POSTER SESSION
NETWORKING - DRINKS RECEPTION - DRAGON’S DEN
LUNCH - EXHIBITION - POSTERS
Wednesday September 2nd
Room: Ironbridge
TIME SPEAKER TITLE
Session Chairs
PLENARY KEYNOTE: ROOM - IRONBRIDGE
The Kinetics of Drug-Receptor Binding: Why It Is Important and How We Can Measure It
Biased Ligand Quantification in Drug Discovery: From Theory to High Throughput Screening to Identify New Biased µ Opioid Receptor Agonists
Efficacy and Toxicity Assays Using iPS Cells - Utilising Cells Reset to the Manufacturers Default Setting
Functional Screening of Network Activity in Primary Neuronal Cultures Using a Novel Phenotypic Assay Platform
Nanobodies in Cell-Based Screening
Phenotypic Screening for Novel Druggable Targets Using "Protein-Interference"
Steven CharltonUniversity of Nottingham
David WinpennyPfizer Neusentis
Tackling Protein Trafficking Diseases
Julie HolderRoslin Cells Limited
Mattias KarlssonCellectricon AB
Miguel CondeAblynx
Keynote Speaker: Chris TorrancePhoreMost Ltd
Dr David ThomasTraffick Therapeutiques/Thérapeutiques, Inc
CHAIRS: Steve Hill, University of Nottingham. Anne Phelan, Pfizer Neusentis
In recent years, drug discovery has moved towards more complex assay technologies that address questions of direct relevance to human disease. These include: (1) the use human stem cell technologies for drug screening, (2) the establishment of high throughput assays that allow drug discovery to be informed by ligand-binding kinetics, (3) the evaluation of methodologies to exploit the clinical potential of ligand bias, (4) platform technologies to rapidly scan disease pathways for novel drug targets. The Innovation in Assay Development & Screening session at ELRIG Drug Discovery 2015 will cover major developments in this fast moving field.
INNOVATION IN ASSAY DEVELOPMENT & SCREENING
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 13:50
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 18:00
16:00 - 16:30
Rebecca Dixon-Steele, AstraZenecaMark Soave, Nottingham University
Essen Bioscience, Tecan, Sygnature Discovery, Caltag Medsystems, Celenys
13:50 - 14:00 Welcome words from the ELRIG Chairman - Sanj Kumar - IRONBRIDGE
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMMARY
Introduction and Welcome
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
LUNCH - EXHIBITION - POSTERS
Thursday September 3rd
Room: Pattingham
TIME SPEAKER TITLE
Session Chairs
Optimising Oncology Drug Discovery via Partnerships Between Academia and Industry
Building On an Atypical (PKC) Relationship – Innovative Drug Discovery Alliances in Oncology
Targeting Oxygenases for the Regulation of Protein Biosynthesis
Chemical Probes for the Bromodomain of the BRPF Family
Fragment-Based Lead Generation of Reversible Inhibitors for Lysine-Specific Demethylases
“We Must Work Together To Catalyse the Generation of More Novel and More Affordable Cancer Treatments”
Neil ThompsonAstex Pharmaceuticals
Christian DillonCancer Research Technology Discovery Laboratory
Christopher SchofieldOxford University
Paul FishUCL School of Pharmacy
Ulf BrembergBeactica
Keynote Speaker: Chas BountraSGC, University of Oxford
ONCOLOGY DRUG TARGETS
The translation of emerging knowledge of cancer biology into novel therapies remains a great challenge in drug discovery, and requires early collaboration between key stakeholders in academia and industry to ensure that the most relevant and actionable targets are taken forward. This session will focus on academia-industry collaboration models established in recent years, with sharing of examples of successful outcomes and lessons learned. A secondary focus will be on epigenetic mechanisms in cancer where pioneering work from organizations such as the Structural Genomics Consortium, has revealed a large number of potentially druggable proteins involved in the writing, reading and erasure of epigenetic marks.
CHAIRS: Herbie Newell, Newcastle University. Hamish Ryder, Cancer Research Technology
PLENARY KEYNOTE: ROOM - IRONBRIDGEThe Development of New Therapeutics for Respiratory Inflammation
Professor Tracy HussellManchester Collaborative Centre forInflammation Research
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 14:00
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 17:00
16:00 - 16:30
CLOSE OF CONFERENCE - with prize draw - IRONBRIDGE
Rachel McMenamin, Mission TherapeuticsAhmad Kamal, MRC Technology
Cisbio, Perkin Elmer
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMARY
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
LUNCH - EXHIBITION - POSTERS
Thursday September 3rd
Room: Beckbury
TIME SPEAKER TITLE
Session Chairs
Modelling Cardiovascular Disease with Pluripotent Stem Cells: a High-Content Approach
Accelerating Human iPSC in vitro Disease Modeling by Introducing Targeted Gene Mutations in Isogenic Cell Lines Through the CRISPR/Cas9 Nuclease System
Adoptive T cell Therapy for Cancer
Hematopoietic Stem Cell Based Gene Therapy for the Treatment of Lysosomal Storage Disorders
Gene Therapy for Choroideremia, an Inherited Cause of Blindness
How Stem Cells Signal to Host Immune Cells
Gabor FoldesNational Heart and Lung Institute, Imperial College London
Vania BroccoliItalian Research Council (CNR) and Ospedale San Raffaele
David GilhamInstitute of Cancer Sciences,Manchester University
Alessandra BiffiTIGET, IRCCS San Raffaele Scientific Institute
Alun BarnardOxford University
Keynote Speaker: Stefano Pluchino Wellcome Trust-MRC Stem Cell Institute, University of Cambridge (UK)
CHAIRS: Aniz Girach, NightstaRx. Angela Gritti, San Raffaele Telethon Institute for Gene Therapy (TIGET)
Gene- and cell-based therapies are fast-growing forms of personalized medicine that rely on steady advances in gene transfer technologies, stem cell manipulation and the growing capacity for genetic reprogramming of mammalian cells. They may fulfill the promise of safe and effective therapies for currently untreatable diseases. The session will describe the latest developments and the crucial challenges for this field, touching on basic science, pre-clinical and clinical studies, with an emphasis on gene therapy approaches for blood, ocular and neurodegenerative disorders, and with a special insight in novel approaches aimed to generate transplantable neuronal populations from induced pluripotent stem cells.
CELL AND GENE THERAPY
PLENARY KEYNOTE: ROOM - IRONBRIDGEThe Development of New Therapeutics for Respiratory Inflammation
Professor Tracy HussellManchester Collaborative Centre forInflammation Research
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 14:00
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 17:00
16:00 - 16:30
Introduction and Welcome
CLOSE OF CONFERENCE - with prize draw - IRONBRIDGE
Vasco Meneghini, San Raffaele Telethon Institute for Gene Therapy (TIGET)
Chemometec A/S, Cambridge Bioscience Limited, QuantaCell, PAA
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMMARY
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 14:00
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 17:00
16:00 - 16:30
Introduction and Welcome
COFFEE BREAK
POSTER TASTERS
SNAPSHOT PRESENTATIONS
CLOSE OF CONFERENCE - with prize draw - IRONBRIDGE
LUNCH - EXHIBITION - POSTERS
Thursday September 3rd
Room: Wenlock
TIME SPEAKER TITLESession Chairs
PLENARY KEYNOTE: ROOM - IRONBRIDGE
Development of Cytotoxic Bicyclic Peptide Drug Conjugates and Applications in Molecular Targeted Cancer Therapy
How Information From the Study of Antibody Function Can be Used in the Discovery of Novel Small Molecule Therapeutics
XTEN Protein Polymer for Half-Life Extension and Tumor Drug Delivery
Fine-Tuned T Cell Receptors for Cancer Immunotherapy
PBD-Based Antibody Drug Conjugates
Towards a New Class of Biotherapeutics Based on Synthetic Genetic Polymers
Dan Teufel Bicycle Therapeutics
Tom CrabbeUCB
The Development of New Therapeutics for Respiratory Inflammation
Volker SchellenbergerAmunix
Bent JakobsenAdaptimmune
John HartleyUniversity College London
Keynote Speaker: Philipp HolligerMRC Laboratory of Molecular Biology
Professor Tracy HussellManchester Collaborative Centre forInflammation Research
CHAIRS: Katy Kettleborough, MRC Technology. Lutz Jermutus, MedImmune
NEW BIOLOGICAL DRUGS & TECHNOLOGIES
The continuing success of biological drugs, in particular monoclonal antibodies but increasingly also other modalities such as peptides, conjugates and multi-selective agents, will be considered in this session. Alongside this, technologies for discovering, optimising and characterising biopharmaceuticals will be discussed. The session will also explore the interface between biological and small molecule drugs: can information from biological drugs help us design better small molecule drugs? how are drugs at the interface of both areas, such as cyclic peptides and small molecule conjugates to peptides, proteins and antibodies, defining novel drug classes?
Basma Al-Sudani, Salford UniversityLaurent Brault, Exquiron
Greiner Bio-One, SAL Scientific Limited, NanoTemper, Technologies GmbH, Stratech Scientific
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
SESSION SUMMARY
Introduction and Welcome
COFFEE BREAK
Increasing Physiological Relevance, Increasing Information: High-Content Phenotypic Screening
Compound Screening and Profiling in Cultured Human Tissues
POSTER TASTERS
SNAPSHOT PRESENTATIONS
Mass Spectrometry Imaging in Drug Discovery – Bridging Between Cells and Tissues
Phenotypic Discovery Using Machine Learning and Image Analysis Methods
KNIME Image Processing - Integrative Open-Source BioImage Analysis
Phenotypic Screening to Identify Novel Targets for Discovery
LUNCH - EXHIBITION - POSTERS
Anne CarpenterBroad Institute of Harvard and MIT
Leo PriceOcellO
Peter WebbornAstraZeneca R&D
Peter HorvathBiological Research Centre of the Hungarian Academy of Sciences
Christian DietzUniversity of Konstanz
Keynote Speaker: Stephen Rees AstraZeneca
Thursday September 3rd
Room: Ironbridge
TIME SPEAKER TITLESession Chairs
PHENOTYPIC DISCOVERY & CELL IMAGING
The renaissance in the use of phenotypic cell-based assays throughout the drug discovery process is an opportunity to combine an approach used intensively in the pre-genomic area with enabling new technologies. Success in the area aligns drug discovery hypotheses with translational disease biology, leading to an anticipated improvement in attrition rates of new medical entities in the clinic. Cellular imaging is a broad field that is being utilised to deliver multiple phenotypic assay opportunities in drug discovery programs (including simple to complex cell cultures, data analysis, and biomarker/phenotype detection), and is advancing rapidly. The Phenotypic discovery and cellular imaging session at ELRIG Drug Discovery 2015 will cover progress in imaging technologies, analytics and cell biology in this lively and quickly progressing field.
CHAIRS: Steve Ludbrook, GlaxoSmithKline. Marc Bickle, Max Planck Institute of Molecular Cell Biology & Genetics
PLENARY KEYNOTE: ROOM - IRONBRIDGEThe Development of New Therapeutics for Respiratory Inflammation
Professor Tracy HussellManchester Collaborative Centre forInflammation Research
9:15 - 10:00
9:10 - 9:15
10:30 - 11:00
10:00 - 10:30
11:00 - 11:30
11:30 - 12:00
12:30 - 14:00
12:00 - 12:30
14:00 - 15:00
15:00 - 15:30
15:30 - 16:00
16:30 - 17:00
16:00 - 16:30
CLOSE OF CONFERENCE - with prize draw - IRONBRIDGE
Daniel Wilcock, AstraZenecaThalia Carreno, University of Sussex
Genedata, IntelliCyt, PhaseFocus, HighRes Biosolutions, Bio Tek Instruments
Publication date 28/08/2015. More detail, abstracts, speaker biogs, etc, are available on our website www.elrig.org or our mobile app ‘ELRIG@.
#ELRIGDD15
TECHNOLOGY FORUMS
This session contains four workshops, set in the round to promote discussion and debate within each topic area. There will be a chair leading the discussion, but your participation is very much encouraged. Please come along and join in the discussions.
CHAIRS: Eddy Littler, Uli Schopfer, Geoff Holdgate and Christian Ottman
9:10 - 10:30 Anti-InfectivesOne of the greatest health challenges is the emergence of new pathogens and those with resistance to current drugs. This workshop will focus upon what are the emerging pathogens and what are the targets or technologies that are being applied or developed to tackle these challenges. Topics to be included are emerging haemorrhagic viruses (Ebola), diseases with known causative agents with poor treatment (RSV and HBV) and bacterial challenges (gram negative organisms).
Eddy Littler, DomainexKen Powell, Chairman of ReViralSivaramesh Wigneshweraraj, Imperial CollegeDavid Hughes, Chief Technology Officer CNBIOLaura Lane, Warwick Ventures
TIME PANELIST TITLE
10:30 - 11:00 COFFEE BREAK
11:00 - 12:30 Future of HTSIn this panel discussion we will explore some of the forces that will shape the future of HTS, and of lead discovery in general. Experts from big Pharma, Biotec and academia will explore developments in science and technology and partnership models that allow taking advantage of these developments in times of constrained budgets.•Role/Impact of new technologies (CRISPR, iPS, 3D, microfluidics, others…)•Future role of CROs in times of increasingly constraint budgets•Focused vs large scale screening•Target-based, phenotypic and what is next
Ulrich Schopfer, NovartisSteve Rees, AstraZenecaDirk Ullmann, EvotecPhil Gribbon, EU-OPENSCREEN Fraunhofer IME GermanyPeter Roevens, Janssen
12:30 - 14:00
14:00 - 15:00
LUNCH - EXHIBITION - POSTERS
PLENARY KEYNOTE: ROOM - IRONBRIDGEThe Development of New Therapeutics for respiratory inflammation
Professor Tracy HussellManchester Collaborative Centre forInflammation Research
12:30 - 14:00 Geoff Holdgate, AstraZenecaJon Hutchinson, GSKChris Abell, University of CambridgeJohn Unitt, Sygnature DiscoveryMichelle Heathcote, ProximagenWalter Ward, Walter Ward Consultancy & Training
15:00 - 16:30 Protein - Protein Interaction Drug DiscoveryMore than 300,000 Protein-Protein Interactions (PPIs) can be found in human cells. Specific and potent modulation of PPIs would tremendously enlarge the "druggable genome" enabling novel ways of drug discovery for essentially every human disease. We have seen great progress in the last 10 - 15 years in the identification and development of PPI modulators, however, PPIs are still considered as one of the most demanding targets in drug discovery. In this forum we will discuss recent progress, medicinal chemistry and clinical challenges and the future prospects of PPI modulators to fulfill their tremendous potential as novel therapeutic agents.
Christian Ottman, Technical University, EindhovenDavid Thomas, Traffick Therapeutiques, Inc.Mike Waring, AstraZeneca/Newcastle UniversityTom Crabbe, UCBAlicia Higueruelo, TIMBAL-DBOlivier Sperandio, iPPI-DB
16:30 - 17:00 CLOSE OF CONFERENCE - with prize draw
Thursday September 3rd
Room: Coalport
Enzymology Used Throughout Drug DiscoveryThe combination of activity data from biochemical assays, binding data from biophysical methods and structural information has allowed new perspectives for the application of enzymology in drug discovery. In addition to discussing traditional approaches including the development of multi-substrate assays and the characterisation of pan assay interference compounds, which are crucial activities for optimizing assay readout and the identification of true hits, this forum will also explore the characterisation of slow-binding and irreversible compounds, as there is now an increasing interest in guiding the development of structure activity relationships by means of binding kinetics and residence times.
POSTER COMPETITION
TECHNOLOGY PRIZE
SLAS YOUNG SCIENTIST PRIZE
Every year at ELRIG Drug Discovery we get a fantastic range of Posters presented. We invite YOU, the delegates, to vote for what you think is the best poster.
Simply fill in your choice on the voting form in your programme and return it to the ELRIG registration desk.The winner will be announced in the closing address ( Ironbridge, 16:30, Thurday 3rd September). Votes returned by 3pm on Thursday 3rd will be entered into a PRIZE DRAW – also made at the closing address. (Please note you need to be there in person to win).
Please have a good look around the exhibition: it’s the exhibitors’ support that keeps ELRIG events free to attend.
We invite YOU, the delegates, to vote for what you think is the best technology being shown in the exhibition.
Fill in your choice on the voting form in your programme and return it to the ELRIG registration desk. The winner will be announced in the closing address (Ironbridge, 16:30, Thur 3rd). Votes returned by 3pm on Thurs 3rd will be entered into a PRIZE DRAW – also made at the closing address. (Again please note that you need to be there to win).
The winner will be invited to present and participate in the Student Poster Competition at the 4th SLAS Annual Conference and Exhibition, SLAS2016, January 23-27, 2016 at the San Diego Convention Centre, SanDiago, California, USA.
SLAS Young Scientist Award winners receive a US$500 cash prize, roundtrip economy airfare, shared hotel accommodation and conference registration for SLAS2016.
Eligibility: Applicants should ideally be a student or within the first five years of their professional scientific research career.
Judging: Will be by a panel of eminent scientists appointed by SLAS and ELRIG. Judging will take place during the whole event, although judges may well (anonymously) come by and chat with you during the official Poster Session from 16:30 to 18:00 on Wednesday September 2. So do your best to be there!
Presentation of the award: Will take place at the conference closing ceremony, and be announced in the ELRIG and SLAS news media.
Students, graduates and post-docs are welcome to compete for the SLAS Young Scientist Award at ELRIG Drug Discovery 2015.
How to enter
1. Posters must have already been submitted, accepted, and on the list for ELRIG DD’15.2. Come to the ELRIG registration Desk and tell us your poster number. Do this before 16:00 on Wednesday September 2 ( i.e. before the poster session starts).
www.elrig.org
European LaboratoryResearch & Innovation Group
THE ELRIG TECHNOLOGY PRIZE
Please vote for what you think is the most interesting / innovative technology you have seen at the exhibition.
Company:
Technology:
THE ELRIG POSTER PRIZE
Please vote for what you think is the most interesting poster you have seen at this event.
Poster Number:
VOTING
All votes will be entered into a prize draw for a Samsung Galaxy Tablet at the closing session
Name:
Company:
Mobile No:
E-mail:
Please return forms to the ELRIG desk by3 PM ON DAY 2 - Thank you!
DRUG DISCOVERY ‘15
2ND - 3RD SEPTEMBER 2015
TELFORD INTERNATIONAL CONFERENCE CENTRE
NETWORKING
OUR MOBILE APP - ‘ELRIG’
Drug Discovery 2015 is an excellent way to network with like - minded individuals. There are a number of ways you can do this:
• Download our free App : “ELRIG” ( iOs or Android ) ~~/QR code~~ • Complete your profile • Open the DD’15 event • Now – enter the “Networking Form” • There are discussion groups for each session topic, or create a new one: join in! • View the delegates • The “Search” button will find anyone connected with the search words you enter • You can contact people by e-mailing from within the app. Or, you can meet in person in the Networking Zone. There are café tables in the “Networking Zone” which are flagged for each session topic.
All our event information in the palm of your hand for iOS or Android
Free to download :• Programme ( searchable )• Speakers, Biogs, Abstracts• Exhibitors Guide• Posters Guide
• NETWORK • Delegates List • Intelligent Search function • Contact via e-mail • Networking Discussion Forum
Download the app using the QR code.
WI-FI is free at the venue:
Network: TICUK ( upper case )Username: elrig ( lower case )Password: 2015
DRINKS RECEPTION
DRAGON’S DENS
Wine, beer, soft drinks, & nibbles will be served in the Exhibition Hall, giving delegates a chance to mix, chat, network and talk to the exhibitors.Watch the Dragon’s Den on the set in the main hall.
TWO drinks tickets each are provided in your delegate bag : exchange these for your choice of drinks from the servers.
With thanks to our drinks reception sponsor:
Come and hear real entrepreneurs from the show pitch new businesses and products to our panel of expert, ‘Dragons’ - the only thing that’s not real is the money on the table.
“Entertaining & informative”
Wednesday September 2nd
Exhibition Hall - 17:00 - 18:00
Wednesday September 2nd
Exhibition Hall - 17:00 - 18:00
EXHIBITORS
INNOVATION ZONE
BioTek Instrumentswww.biotek.com
BlueCatBio GmbHwww.bluecatbio.com
Bigneatwww.bigneat.co.uk
Abcam Plcwww.abcam.com
AstraZenecawww.astrazeneca.co.uk
Axol Bioscience Ltdwww.axolbio.com
BMG LABTECH Ltdwww.bmglabtech.com
Caltag Medsystems Ltdwww.caltagmedsystems.co.uk
Cambridge Biosciencewww.bioscience.co.uk
Cellectricon ABwww.cellectricon.com
Cellular Dynamics International www.cellulardynamics.com
Essen BioScience www.essenbio.com
Formulatrix, Incwww.formulatrix.com
Gilson Scientific Ltdwww.gilsonuk.com
Horizon Discoverywww.horizondiscovery.com
INTEGRA Bioscienceswww.integra-biosciences.com
IntelliCyt Corporationwww.intellicyt.com
Nexcelom BioScience Ltdwww.nexcelom.com
Peak Analysis and Automationwww.paa-automation.com
PerkinElmerwww.perkinelmer.com
Phasefocuswww.phasefocus.com
Promega UK Ltdwww.promega.co.uk
Sigma-Aldrich www.sigmaaldrich.com
Chemometec A/Swww.chemometec.com
HSC Pharmawww.hcs-pharma.com
Celenyswww.celenys.com
MIP Diagnostics Limited
N8 Researchwww.n8research.org.uk
Quantacellwww.quantacell.com
SAL Scientificwww.salscientific.com
The Research Networkwww.theresearchnetwork.co.uk
Tigris Biosciencewww.tigrisbioscience.com
4titude Limitedwww.4ti.co.uk
Agilent Technologieswww.agilent.com
AMS Biotechnology (Europe)www.amsbio.com
Andrew Alliancewww.andrewalliance.com
Aptamer Group Limitedwww.aptamergroup.co.uk
Beckman Coulter UK Limitedwww.beckmancoulter.com
Cell Signaling Technologywww.cellsignal.com
Cisbio Bioassayswww.cisbio.com
Contained Air Solutionswww.containedairsolutions.co.uk
Corning Life Scienceswww.corning.com/lifesciences
Dotmatics Limitedwww.dotmatics.com
Dundee University Drug Discovery Unitwww.drugdiscovery.dundee.ac.uk
EasyFairswww.easyfairs.com
Eurofins Pharma Discovery www.essenbio.com
Eventflo www.myeventflo.com
Genedatawww.genedata.com
Greiner Bio-One Ltdwww.greinerbiooine.com
Hamamatsu Phonics UK Ltdwww.hamamatsu.com
Hamilton Robotics Ltdwww.hamiltonrobotics.com
HighRes Biosolutions Ltdwww.highresbio.com
IKKO-ZU Corporationwww.bioscience-ik.com
Lab Services bvwww.lab-services.nl/
Labcytewww.labcyte.com
Lablogic Systems Ltdwww.lablogic.com
Luminexwww.luminexcorp.com
Miltenyl Biotec GmbHwww.miltenyibiotec.com
Molecular Devices (UK) Ltdwww.moleculardevices.com
NanoTemper Technologies Ltdwww.nanotemper-technologies.com
Sartorius Stedim Biotechwww.tapbiosystems.com
SLAS www.slas.org
Sophion www.biolinscientific.com/sophion
Tecan www.tecan.com
Stratech Scientific Ltd www.stratech.co.uk
Sygnature Discovery www.sygnaturediscovery.com
Titian Software Ltdwww.tition.co.uk
Venomtech Ltdwww.venomtech.co.uk
Zinsser Analytic GmbHwww.zinsser-analytic.com
DRUG DISCOVERY SPONSORS 2016
LANGTON HOWARTH CHALLENGE
EVENT SPONSORS
MEDIA PARTNERS
PARTNERS
WIN WIN WIN!!!
Be sure to visit Langton Howarth in the recruitment zone where we can discuss your hiring requirements and great opportunities available RIGHT NOW as well as testing your reactions on our interactive game where you could win a super car track day!
FUTURE ELRIG MEETINGS
Make sure you are part of these events. Book your place NOW!For more information please contact the ELRIG team:
Email: [email protected] Tel: +44 (0)1904 405 177 Web: www.elrig.org
Become part of the UK’s most innovative life science network
4th - 5th November 2015ELRIG ‘Pop-Up’ at Lab InnovationsNEC, Birmingham, UK
11th November 2015Mass SpectrometryLakeside Conference Centre, York, UK
23rd March 2016Research & Innovation ‘16Trent Vineyard, Nottingham, UK
4th May 2016Robotics & AutomationFesto, Northampton, UK
14th - 15th June 2016Recombinant Protein TechnologyAstraZeneca. Molndal, Sweden
1st - 2nd September 2016Drug Discovery ‘16Telford International Conference Centre, UK
22nd - 23rd November 2016Pharmaceutical Flow Cytometry & ImagingGSK, Stevenage, UK